Oncology's mission is simply stated: to cure or control cancer with breakthrough medicines. This means developing new cancer medicines with both care and speed, and appropriately communicating the latest clinical data on our marketed medicines, so that oncologists and patients can make the most informed treatment choices. Pfizer Oncology has one of the industry's fastest growing pipelines of potential new medicines. Our goal is to develop the most promising of these compounds into treatments that target the right drug for the right patient at the right time.
That's the question oncologists expect Pfizer to answer for patients. The science for treating cancer is moving so quickly, and the stakes for patients are so huge, that we often become a trusted partner with oncologists in getting the patient to "tomorrow." That's why Pfizer's creation of the Oncology business unit is so critical. We have the ability to shape the science throughout a medicine's late-stage development, approval and life cycle. We can put the right number of medical experts into the field, so that oncologists get the fastest, most complete information when they ask the crucial question—"What's the best science available right now?"
At the same time, we're Pfizer, the top name in prescription medicines. We're putting our full scope and scale behind our drive for leadership in oncology. With a broad array of compounds currently in development, Pfizer's scientists are advancing research in some of the most prevalent and difficult-to-treat cancers, including lung, prostate, colorectal and breast cancers. As the science in oncology continues to evolve, Pfizer is leading clinical research to create a personalized approach to treatment based on the molecular and biologic make-up of the disease.
There's amazing opportunity here, but it's rooted in a quality that transcends both business and science. That's trust—the trust that Pfizer will offer oncologists and patients the best advances to treat cancer.